Your institution may have access to this item. Find your institution then sign in to continue.
Title
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma.
Abstract
The article focuses on the Food and Drug Administration (FDA)'s approval of nivolumab a PD-1 inhibitor, for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and above, a decision supported by the CheckMate-76K study. Nivolumab demonstrated significantly improved recurrence-free survival rates compared to placebo, highlighting its efficacy in this specific setting, with common adverse reactions including fatigue, musculoskeletal pain, and diarrhea.